UNSPSC 51331606: Lometraline hydrochloride

This classification denotes an antiparkinsonian agent with the molecular formula C13H18ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2OJ193WGR, chemically known as 8-chloro-1,2,3,4-tetrahydro-5-methoxy-n,n-dimethyl-1-naphthylamine hydrochloride but more generally known as lometraline hydrochloride, which bears US NIH Compound Identifier 34788. Most nations, for tariff and trade purposes, schedule lometraline hydrochloride under HS 29222900 and SITC 51462.

As of Q4 2014, LOMETRALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lometraline hydrochloride bears US NLM identifiers UMLS ID C0888036 and NCI Concept Code C81563. SMILES: CN(C)C1CCCC2C1C(CCC2OC)CL.CL.

UNSPSC 51331606 Lometraline hydrochloride is a Commodity code that, based on recent state and local solicitations, does not align with the actual pharmaceutical procurement activity being conducted. The three recent opportunities posted under this code involve naloxone and drug deactivation systems (Seminole County, Florida), therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference lometraline hydrochloride specifically or align with the nominal scope of this commodity code. The issuing bodies represent a mix of county health departments, state health agencies, and cooperative purchasing alliances, indicating fragmented procurement authority across health and human services functions.

Geographic activity appears concentrated in Florida, Texas, and Minnesota based on the recent postings, with the cooperative purchasing mechanism (MMCAP) extending to participating states including Oregon. Representative recent opportunities include Seminole County's IFB for naloxone and safe drug deactivation systems (due July 26, 2023) with quarterly deliveries; the Texas HHS Commission's RFI for direct-to-manufacturer prescription capabilities (posted April 3, 2026); and the Minnesota Department of Administration's RFP through MMCAP for generic pharmaceuticals and OTC products (due March 26, 2026, with contract effectiveness July 1, 2026). The code shows little relevant recent activity aligned with lometraline hydrochloride procurement, suggesting either a classification mismatch in state and local procurement systems or minimal actual demand for this specific pharmaceutical product under the code designation.